

[The decisions of the Formulary Group meeting \(Tuesday 21 May 2024\) will be published by 05 June 2024.](#)

**Publication schedule**

This information is updated monthly.

**Formulary Group work programme**

The Group meets monthly on the third Tuesday of each month (excluding July and December). The following list includes medicines that will be scheduled for review in the next three to four months. It is indicative and may be subject to change.

Medicine and indication	Meeting date
<b>apalutamide 60mg film-coated tablets (Erleada®)</b> <b>SMC 2579</b>	
Indication: treatment of adults with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.	May 2024
<b>Asacol® 400mg MR tablets (mesalazine)</b> <b>Discontinued/withdrawn</b>	
Indication: - treatment of mild to moderate acute exacerbations of ulcerative colitis and maintenance of remission - maintenance of remission in Crohn's ileo-colitis.	May 2024
<b>atovaquone 750mg/5mL oral suspension</b> <b>FG1 451/22</b>	
Indication: (off-label) for the prevention of Pneumocystis carinii pneumonia. Restriction: Second-line option for patients where co-trimoxazole is not effective, not tolerated or contraindicated.	Q4 2024
<b>clonidine 25micrograms, 100micrograms tablets</b> <b>Formulary review</b>	
Indication: off-label for children and adolescents 6 years and older for the management of ADHD in those unresponsive to or unable to tolerate treatment with stimulants, atomoxetine or guanfacine.	May 2024
<b>Daktacort® 2%/1% w/w cream (miconazole/hydrocortisone) - 30g pack</b> <b>Discontinued/withdrawn</b>	
Indication: for the topical treatment of inflamed dermatoses where infection by susceptible organisms and inflammation co-exist, e.g., intertrigo and infected eczema.	May 2024

Medicine and indication	Meeting date
<b>dostarlimab 500mg concentrate for solution for infusion (Jemperli®)</b> <b>SMC 2635</b>	
Indication: in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	Q3 2024
<b>dupilumab 300mg solution for injection in pre-filled syringe or pre-filled pen (Dupixent®)</b> <b>SMC 2598</b>	
Indication: for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.	May 2024
<b>eflornithine 11.5% cream (Vaniqa®)</b> <b>Formulary review 159/05</b>	
Indication: treatment of facial hirsutism in women. Restriction: women for whom alternative drug therapy is ineffective, contra indicated or considered inappropriate.	May 2024
<b>eladocagene exuparvovec <math>2.8 \times 10^{11}</math> vector genomes (vg)/0.5mL solution for infusion (Upstaza®)</b> <b>SMC 2586</b>	
Indication: for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype.	May 2024
<b>foslevodopa-foscarbidopa 240mg/mL + 12mg/mL solution for infusion (Produodopa®)</b> <b>SMC 2574</b>	
Indication: treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. SMC restriction: for use in patients not eligible for deep brain stimulation (DBS).	June 2024
<b>ivosidenib 250mg film-coated tablet (Tibsovo®)</b> <b>SMC 2615</b>	
Indication: in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.	Q3 2024

Medicine and indication	Meeting date
<b>Klean-Prep® oral powder 69g sachets sugar free</b>	
<b>Discontinued/withdrawn</b>	
Indication: for colonic lavage prior to diagnostic examination or surgical procedures requiring a clean colon, e.g. colonoscopy, barium enema or colonic resection.	May 2024
<b>mavacamten 2.5mg, 5mg, 10mg, 15mg hard capsules (Camzyos®)</b>	
<b>SMC 2618</b>	
Indication: treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Q3 2024
<b>mirikizumab 100mg, 300mg solution for injection in pre-filled pen and concentrate for solution for infusion (OmvoH®)</b>	
<b>SMC 2650</b>	
Indication: for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.	Q3 2024
<b>nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)</b>	
<b>SMC 2503</b>	
Indication: as monotherapy for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression $\geq 1\%$ , who are at high risk of recurrence after undergoing radical resection of MIUC.	May 2024
<b>pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)</b>	
<b>SMC 2526</b>	
Indication: as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB or IIC melanoma and who have undergone complete resection.	May 2024
<b>ritlecitinib tosylate 50mg hard capsules (Litfulo®)</b>	
<b>SMC 2610</b>	
Indication: for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.	Q4 2024

Medicine and indication	Meeting date
<p><b>secukinumab 150mg, 300mg solution for injection in pre-filled pen or pre-filled syringe (Cosentyx®)</b></p>	
<p><b>SMC 2592</b></p>	
<p>Indication: for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.</p>	
<p>SMC restriction: for use in adult patients with active moderate to severe HS for whom adalimumab is contraindicated or otherwise unsuitable, including those who have failed to respond or have lost response to prior adalimumab treatment.</p>	<p>Q3 2024</p>
<p><b>selpercatinib 40mg, 80mg hard capsules (Retsevmo®)</b></p>	
<p><b>SMC 2573</b></p>	
<p>Indication: monotherapy for the treatment of adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.</p>	
<p>SMC restriction: for use in treatment-naïve patients who have not previously received a RET-inhibitor or any other systemic treatments for their advanced stage of disease.</p>	<p>June 2024</p>
<p><b>sodium zirconium cyclosilicate 5g and 10g powder for oral suspension (Lokelma®)</b></p>	
<p><b>SMC 2288</b></p>	
<p>Indication: for the treatment of hyperkalaemia in adult patients.</p>	
<p>SMC restriction: patients with hyperkalaemia (defined as a serum potassium of &gt;6.0mmol/L) with chronic kidney disease (CKD) stage 3b to 5 and/or heart failure who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system inhibitor (RAASi) therapy to maintain a clinically acceptable serum potassium level (normokalaemia)</p>	<p>June 2024</p>
<p><b>Symbicort® Turbohaler® 200micrograms/6micrograms/inhalation, inhalation powder (budesonide/formoterol)</b></p>	
<p><b>SMC 2622</b></p>	
<p>Indication: as reliever therapy for adults and adolescents (12 years and older) with mild asthma.</p>	
<p>SMC restriction: for use in patients who would otherwise receive low dose inhaled corticosteroid (ICS) maintenance therapy plus short-acting beta-2 adrenoceptor agonist (SABA) as needed.</p>	<p>May 2024</p>

END